LNC Therapeutics, a company specialising in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has closed a EUR6.5 million C series funding round.
This new round, co-led by Seventure Partner, brings together a consortium of historic investors and a family office. Since its creation in 2010, LNC Therapeutics has raised a total of EUR16.5 million.
“This funding round of EUR6.5 million establishes LNC Therapeutics as a key player in the treatment of obesity and metabolic disorders through an action on the gut microbiota,” says Jean-Luc Treillou, LNC Therapeutics’ CEO. “Our recent clinical trial on obese patients indicated that visceral fat loss in this population was correlated with a modulation of the gut microbiota, specifically with a bacterial family known for its anti-obesity potential.
“Hence, our current objective is to develop new drug candidates whose mechanism of action requires an interaction with the gut microbiota and the intestinal membrane. Targeted therapeutic indications include pathologies caused by excessive visceral fat accumulation and chronic inflammation such as obesity and NASH”.
